Can Peptides Cause Diarrhea? Which Ones Do and Why

Trial figures below measure different things, so the third column says exactly what each number counts.

Across the GLP-1 class as a whole, nausea, vomiting, diarrhea and constipation occur in roughly 30% to 50% of patients, concentrated at initiation and dose escalation (Singhani et al., Nutr Clin Pract, 2026, PMID 42808923). Everything below rank 5 is a different world: the risk is real but small, and usually traceable to something other than the peptide sequence.

None of the compounds in this table except semaglutide and tirzepatide is FDA-approved for the uses described. Retatrutide and cagrilintide are investigational; the rest are research compounds.

Think of a bakery with one slow oven and a fast packing line. The oven (your stomach) takes twice as long, so loaves sit and the smell makes you queasy. But whatever finally reaches the packing line arrives half-baked, and the line runs at full speed with no time to dry anything out. Nausea comes from the oven. Diarrhea comes from the line.

Literally stated: GLP-1 receptor agonists slow gastric emptying, which produces the fullness and nausea, while the diarrhea arises further down through altered intestinal motility and secretion. The nausea mechanism is well mapped; the diarrhea mechanism is less settled and is treated as a mix of transit changes and poorly digested, osmotically active food reaching the colon (Singhani et al., Nutr Clin Pract, 2026, PMID 42808923). The rest of the class picture, with per-drug numbers, is in GLP-1 side effects statistics.

Three practical consequences follow. First, fat makes it worse: a stomach that empties slowly on a fatty meal sends a greasy, unemulsified bolus downstream, and fatty loose stools on injection day are the classic result. Second, the timing is dose-linked. In the semaglutide STEP trials GI events were transient, mild to moderate in 98.1% of cases, and clustered during or shortly after dose escalation, with only 4.3% of participants stopping because of them (Wharton et al., Diabetes Obes Metab, 2022, PMID 34514682). Third, the stomach and the bowel can disagree: the same person can be constipated on week 2 and loose on week 5, which is why how long retatrutide diarrhea lasts is a timeline question rather than a yes-or-no one.

Below the GLP-1 and amylin class, no peptide has a trial-measured diarrhea rate, and the honest statement is that rigorous human safety data for BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, sermorelin and TB-500 are scarce (Mendias et al., Sports Med, 2026, PMID 41966639). Absence of a signal is weaker than evidence of safety, and the table ranks accordingly.

BPC-157. A gastric-juice-derived peptide studied mainly for gut protection. The only human dosing report, an intravenous pilot, found no adverse effects at up to 20 mg in 2 healthy adults (Lee et al., Altern Ther Health Med, 2025, PMID 40131143). Two people is not a safety dataset. Oral capsules occasionally loosen stool for the first 3 to 5 days; injected BPC-157 almost never does.

KPV. This alpha-MSH tripeptide is taken up by the intestinal PepT1 transporter and reduced colitis in mouse models rather than causing it (Dalmasso et al., Gastroenterology, 2008, PMID 18061177). Diarrhea reports are rare and usually track a change in the oral product, not the peptide. Dosing is in the KPV dosage chart.

CJC-1295, ipamorelin, sermorelin. Growth-hormone secretagogues act on the pituitary, not the gut. The CJC-1295 trial in healthy adults reported no serious adverse reactions and described the compound as relatively well tolerated at 30 to 60 mcg/kg (Teichman et al., J Clin Endocrinol Metab, 2006, PMID 16352683); GI effects were not a reported signal. Flushing, water retention and injection-site reactions are the complaints that do show up, as the CJC-1295 dosage guide covers.

MOTS-c, GHK-Cu, TB-500. No human adverse-event dataset exists for any of the three. GHK-Cu is used topically or injected and never contacts the intestinal lining. MOTS-c and TB-500 user reports center on fatigue, headache and site reactions; see MOTS-c side effects and TB-500 side effects. If one of these gives you diarrhea, suspect the next section before the peptide.

For anything outside the GLP-1 class, the realistic suspects are what came with the peptide.

Sugar alcohols are the most common missed cause. They are poorly absorbed, and GI disturbances including osmotic diarrhea are a known dose-dependent effect of consuming them (Mäkinen, Int J Dent, 2016, PMID 27840639). A "peptide" diarrhea that appears only after flavored collagen or a sweetened electrolyte mix is almost always this.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative and causes no diarrhea when injected subcutaneously. The real water risk is the opposite one: tap water, store-bought distilled water, or a vial kept past its window grows bacteria, and the first sign may be an infection rather than a loose stool. Bacteriostatic water vs sterile water explains the difference, and how long reconstituted peptides last gives the discard dates.

Timing and pattern separate the causes faster than any test.

Scenario: blaming ipamorelin. You start CJC-1295/ipamorelin and a chocolate collagen powder the same Monday and get loose stools by Wednesday. The secretagogue has no GI mechanism; the 15 g scoop of sweetened collagen does. Fix: drop the powder for 3 days before you touch the peptide dose.

Scenario: a 4-day run on tirzepatide at 10 mg. Four days of loose stools, half your usual food intake, no fever. That matches the 21.2% trial rate at that dose and the escalation window. Fix: hold the dose rather than climbing to 12.5 mg, eat low-fat, and check your other medications in tirzepatide drug interactions, since metformin and some antibiotics add their own loose stools. The units are in the tirzepatide dosage calculator.

The multidisciplinary consensus on GLP-1 GI events recommends slow escalation, smaller meals, less fat, and hydration as first-line steps (Gorgojo-Martínez et al., J Clin Med, 2022, PMID 36614945). In practice:

1. 1.Hold the dose. Do not escalate while stools are loose. Give each GLP-1 step at least 4 weeks.
2. 2.Cut fat on injection day. Keep meals under 15 g of fat and 300 calories for the first 48 hours after each dose.
3. 3.Sip, do not gulp. 2 to 3 liters a day in small amounts; add an unsweetened electrolyte source if stools are watery.
4. 4.Remove the sweeteners. Switch any flavored collagen, protein or electrolyte powder to an unflavored version for one week.
5. 5.Audit the water and the vial. Bacteriostatic water, a vial inside its discard window, and a reputable source with a COA.
6. 6.Use loperamide sparingly. It controls a bad day but masks the pattern you need to read.
7. 7.Move the injection to the morning if nighttime urgency is the main problem; the timing logic in how to relieve nausea from semaglutide applies to diarrhea in reverse.

Discontinuation for GI events stayed under 5% in the semaglutide trials and under 7.1% at any tirzepatide dose (Jastreboff et al., N Engl J Med, 2022, PMID 35658024). Most people finish escalation without stopping. The broader rules for sourcing, storage and dose discipline are in the peptide safety guide.

Stop the compound and get seen the same day if any of these appear:

• Six or more watery stools in 24 hours, or diarrhea lasting beyond 7 days at a stable dose
• Blood or black, tarry stool
• Fever of 38 °C (100.4 °F) or higher alongside the diarrhea
• Dark urine, dizziness on standing, a racing heart, or no urine for 8 hours
• Severe abdominal pain that does not ease after a bowel movement, which on a GLP-1 peptide needs pancreatitis and gallbladder causes excluded
• Vomiting that prevents you keeping fluids down for 12 hours

Nausea and diarrhea were the most common adverse events in the STEP 1 trial and were typically transient and mild to moderate (Wilding et al., N Engl J Med, 2021, PMID 33567185). The list above describes the minority that is neither. A dehydrated person on a drug that halves food intake can slide into electrolyte trouble inside two days, and no dose adjustment fixes that from home.